Top Quality Anti Cancer Drug Erlotinib Hydrochloride Powder

Details:

                                                                             Top Quality Anti Cancer Drug Erlotinib Hydrochloride Powder

1. Erlotinib hydrochloride is a kind of small molecule epidermal growth factor receptor tyrosine kinase reversible inhibitor. It is mainly used for
the second-line or third-line treatment of locally advanced or metastatic non-small cell lung cancer and for the treatment of pancreatic cancer.
 

2. HER-1/EGFR tyrosine kinase inhibitors.

3.Erlotinib has shown a survival benefit in the treatment of lung cancer in phase III trials. The SATURN (Sequential Tarceva in Unresectable NSCLC)
study found that erlotinib added to chemotherapy improved overall survival by 19%, and improved progression-free survival (PFS) by 29%, when
compared to chemotherapy alone.

4.The U.S. Food and Drug Administration (FDA) has approved erlotinib for the treatment of locally advanced or metastatic non-small cell lung
cancer that has failed at least one prior chemotherapy regimen.

5.In November 2005, the FDA approved erlotinib in combination with gemcitabine for treatment of locally advanced, unresectable, or metastatic
pancreatic cancer.

6.In lung cancer, erlotinib has been shown to be effective in patients with or without EGFR mutations, but appears to be more effective in patients
with EGFR mutations. Overall survival, progression-free survival and one-year survival are similar to standard second-line therapy ( pemetrexed).
Overall response rate is about 50% better than standard second-line chemotherapy.Patients who are non-smokers, and light former smokers, with
adenocarcinoma or subtypes like BAC are more likely to have EGFR mutations, but mutations can occur in all types of patients. A test for the
EGFR mutation in cancer patients has been developed by Genzyme.

7.Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found
in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia.
The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.


Julong Bio-Tech Co., Ltd. is located in Xi'an City, Shaanxi Province, China. It is a biotechnology enterprise engaged in the research,
development,production and sales of animal and plant extracts, cosmetics, pharmaceutical raw materials and intermediates. The company has
complete experimental facilities. And advanced testing instruments  ensure the stability of product quality from all aspects. The company has
a complete sales service system, the products are exported to countries all over the world, and have won a good international reputation with
excellent quality and excellent service.

The company has been adhering to the basic principles of "integrity, quality, service, and win-win" to serve customers, constantly strict
requirements, set goals, and implementwin-win development.